The earnings call presented a mixed sentiment with significant advancements in the RSV and immunology programs and a stable financial position. However, it also highlighted challenges with a decline in revenue, increased net loss, and slower enrollment in the RSVPEDs study.

Company Guidance

During the earnings call for Enanta Pharmaceuticals' fiscal second quarter of 2024, the company provided guidance on several key metrics. For the quarter, total revenue was reported at $17.1 million, primarily from royalty revenue tied to AbbVie's MAVYRET sales. The company updated its expense guidance, projecting research and development expenses to range between $125 million and $145 million, reflecting increased investment in its RSV and new immunology programs. General and administrative expenses are expected to be between $50 million and $60 million, influenced by additional stock compensation and legal costs. Enanta concluded the quarter with approximately $300 million in cash and marketable securities, anticipating this will support its existing operations through the third quarter of fiscal 2027. The company is also advancing its RSV and CSU programs, with milestones including data readouts expected in the second half of 2024 and the introduction of a second immunology program.

RSV Program Advancements

Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.

Successful EDP-323 Development

EDP-323 is in a Phase IIa challenge study with anticipated data in Q3 2024, supported by positive Phase I results demonstrating favorable safety and pharmacokinetics.

Pipeline Expansion into Immunology

Introduction of a new immunology program targeting chronic spontaneous urticaria (CSU) with a goal to select a development candidate by Q4 2024.

Stable Financial Position

Enanta ended the quarter with approximately $300 million in cash and marketable securities, projecting sufficient funds to meet anticipated needs through Q3 2027.

---

Enanta Pharmaceuticals (ENTA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ENTA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2025	2025 (Q1)	-1.27 / -	-1.58	―	―	―
Nov 25, 2024	2024 (Q4)	-1.16 / -1.36	-1.33	-2.26% (-0.03)	―	―
Aug 05, 2024	2024 (Q3)	-1.43 / -1.07	-1.86	42.47% (+0.79)	―	―
May 06, 2024	2024 (Q2)	-1.34 / -1.47	-1.79	17.88% (+0.32)
Feb 07, 2024	2024 (Q1)	-1.23 / -1.58	-1.39	-13.67% (-0.19)
Nov 20, 2023	2023 (Q4)	-2.12 / -1.33	-1.27	-4.72% (-0.06)	―
Aug 07, 2023	2023 (Q3)	-2.25 / -1.86	-1.53	-21.57% (-0.33)	―
May 08, 2023	2023 (Q2)	-1.96 / -1.79	-1.63	-9.82% (-0.16)	―
Feb 07, 2023	2023 (Q1)	-1.57 / -1.39	-1.48	6.08% (+0.09)	―
Nov 21, 2022	2022 (Q4)	-1.25 / -1.27	-1.22	-4.10% (-0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ENTA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 25, 2024	$9.01	$8.56	-4.99%
Aug 05, 2024	$12.85	$13.00	+1.17%
May 06, 2024	$14.60	$13.10	-10.27%
Feb 07, 2024	$12.26	$12.36	+0.82%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---